DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.

Insulet has secured US Food and Drug Administration (FDA) clearance for an algorithm advancement within its Omnipod 5 ...

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding. Abbott sells ...

Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will ...

Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that some of them may be ...

In a phase II trial, type 2 diabetes patients treated with amycretin -- an investigational long-acting GLP-1 and amylin receptor agonist -- had up to a 1.8% reduction in HbA1c and up to a 14.5% loss ...

If you are a new investor, healthcare stocks can provide numerous diversification benefits to your portfolio and help enhance its returns in the long run. Healthcare stocks have historically displayed ...

Inhaled Technosphere insulin (TI) failed to meet noninferiority for HbA1c vs subcutaneous rapid-acting analog (RAA) insulin in youth.

Housing inventory is losing momentum, with growth in total supply slowing down, new listings stalling and delistings becoming more common. That's according to a new report from Redfin, the real estate ...